Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records.

He KY, Zhao Y, McPherson EW, Li Q, Xia F, Weng C, Wang K, He MM.

PLoS One. 2016 Dec 8;11(12):e0167847. doi: 10.1371/journal.pone.0167847. eCollection 2016.

2.

NSAIDs and Cell Proliferation in Colorectal Cancer.

Ettarh R, Cullen A, Calamai A.

Pharmaceuticals (Basel). 2010 Jun 24;3(7):2007-2021. Review.

3.

Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.

Williamson T, Bai RY, Staedtke V, Huso D, Riggins GJ.

Oncotarget. 2016 Oct 18;7(42):68571-68584. doi: 10.18632/oncotarget.11851.

4.

Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.

Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK.

JAMA. 2016 Mar 22-29;315(12):1266-75. doi: 10.1001/jama.2016.2522.

5.

Cancer Prevention: Obstacles, Challenges and the Road Ahead.

Meyskens FL Jr, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS.

J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv309. doi: 10.1093/jnci/djv309. Print 2016 Feb. Review.

6.

Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography.

LeGendre-McGhee S, Rice PS, Wall RA, Sprute KJ, Bommireddy R, Luttman AM, Nagle RB, Abril ER, Farrell K, Hsu CH, Roe DJ, Gerner EW, Ignatenko NA, Barton JK.

Cancer Growth Metastasis. 2015 Sep 7;8(Suppl 1):63-80. doi: 10.4137/CGM.S21216. eCollection 2015.

7.

Sulindac, 3,3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis.

Femia AP, Soares PV, Luceri C, Lodovici M, Giannini A, Caderni G.

BMC Cancer. 2015 Sep 3;15:611. doi: 10.1186/s12885-015-1627-9.

8.

Molecular cancer prevention: Current status and future directions.

Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET.

CA Cancer J Clin. 2015 Sep-Oct;65(5):345-83. doi: 10.3322/caac.21287. Epub 2015 Aug 18. Review.

9.

Familial Adenomatous Polyposis (FAP)-A Case Study and Review of Literature.

Dalavi SB, Vedpalsingh TH, Bankar SS, Ahmed MH, Bhosale DN.

J Clin Diagn Res. 2015 Mar;9(3):PD05-6. doi: 10.7860/JCDR/2015/11636.5696. Epub 2015 Mar 1.

10.

Chemoprevention of colorectal cancer.

Lang M, Gasche C.

Dig Dis. 2015;33(1):58-67. doi: 10.1159/000366037. Epub 2014 Dec 17. Review.

11.

BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs.

Leibowitz B, Qiu W, Buchanan ME, Zou F, Vernon P, Moyer MP, Yin XM, Schoen RE, Yu J, Zhang L.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16520-5. doi: 10.1073/pnas.1415178111. Epub 2014 Nov 3.

12.

Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.

Kim HS, Kim T, Kim MK, Suh DH, Chung HH, Song YS.

J Cancer Prev. 2013 Jun;18(2):123-34. Review.

13.

The evolution of colorectal cancer genetics-Part 1: from discovery to practice.

Schlussel AT, Gagliano RA Jr, Seto-Donlon S, Eggerding F, Donlon T, Berenberg J, Lynch HT.

J Gastrointest Oncol. 2014 Oct;5(5):326-35. doi: 10.3978/j.issn.2078-6891.2014.069. Review.

14.

Chemoprevention in patients with genetic risk of colorectal cancers.

Laukaitis CM, Erdman SH, Gerner EW.

Colorectal Cancer. 2012;1(3):225-240.

15.

Regression of Colonic Adenomas After Treatment With Sulindac in Familial Adenomatous Polyposis: A Case With a 2-Year Follow-up Without a Prophylactic Colectomy.

Kim KY, Jeon SW, Park JG, Yu CH, Jang SY, Lee JK, Hwang HY.

Ann Coloproctol. 2014 Aug;30(4):201-4. doi: 10.3393/ac.2014.30.4.201. Epub 2014 Aug 26.

16.

Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis.

Kanik EA, Canbaz H, Colak T, Aydin S.

Curr Ther Res Clin Exp. 2004 Jul;65(4):345-52. doi: 10.1016/j.curtheres.2004.06.001.

17.

Pharmacological and dietary prevention for colorectal cancer.

Nolfo F, Rametta S, Marventano S, Grosso G, Mistretta A, Drago F, Gangi S, Basile F, Biondi A.

BMC Surg. 2013;13 Suppl 2:S16. doi: 10.1186/1471-2482-13-S2-S16. Epub 2013 Oct 8. Review.

18.

Familial adenomatous polyposis of the colon.

Plawski A, Banasiewicz T, Borun P, Kubaszewski L, Krokowicz P, Skrzypczak-Zielinska M, Lubinski J.

Hered Cancer Clin Pract. 2013 Oct 22;11(1):15. doi: 10.1186/1897-4287-11-15.

19.

Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling.

Lang M, Borgmann M, Oberhuber G, Evstatiev R, Jimenez K, Dammann KW, Jambrich M, Khare V, Campregher C, Ristl R, Gasche C.

Mol Cancer. 2013 May 13;12(1):41. doi: 10.1186/1476-4598-12-41.

20.

Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?

Manzano A, PĂ©rez-Segura P.

ScientificWorldJournal. 2012;2012:327341. doi: 10.1100/2012/327341. Epub 2012 Apr 29. Review.

Supplemental Content

Support Center